Rebion
Commercializing Neural Performance Scanning (NPS) to directly detect amblyopia and strabismus in children.
Website: https://www.rebion.co/
Cover Block
Open sources
| Name | Rebion (Rebiscan, Inc. d/b/a Rebion) |
| Tagline | Commercializing Neural Performance Scanning (NPS) to directly detect amblyopia and strabismus in children. |
| Headquarters | Boston, US |
| Stage | Early-revenue-stage [Perplexity Sonar Pro Brief] |
| Business Model | Hardware + Software |
| Industry | Healthtech |
| Technology | Hardware (Medical Device) |
| Geography | North America |
| Growth Profile | Venture Scale |
Links
Open sources
- Website: https://www.rebion.co/
- LinkedIn: https://www.linkedin.com/company/rebion
What an Investor Needs First
Open sources
Rebion is a Boston-based medical device startup commercializing a hardware-first diagnostic platform that directly detects pediatric vision disorders, a technical advance that merits investor attention for its potential to reshape front-line screening. The company's first product, the blinq® pediatric vision scanner, is the only FDA-cleared device that directly identifies amblyopia and strabismus, rather than just predicting risk factors, and delivers a pass-or-refer result in about three seconds [Rebion] [Perplexity Sonar Pro Brief]. This approach, termed Neural Performance Scanning, uses a retinal polarization scan to assess binocular function, positioning the handheld device for use by lay staff in pediatric offices and schools [Perplexity Sonar Pro Brief].
The founding story and team backgrounds are not detailed in public materials, but the technology's development was supported by funding from the National Eye Institute (NEI) and the National Institute of Neurological Disorders and Stroke (NINDS) [Federal Laboratory Consortium / NEI news, Aug 2025]. Rebion operates on a hardware-plus-software business model, selling its scanner to screening programs. Clinical validation underpins the commercial case: a study of 267 children reported the device detected 100% of children needing treatment for amblyopia and strabismus, with a sensitivity of 87.5% for those conditions [Newswire, Sep 2021] [Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS)].
Over the next 12-18 months, the key watchpoints are the commercial rollout pace through distributors like MacGill, any disclosed private financing to scale manufacturing and sales, and the expansion of the Neural Performance Scanning platform into adjacent neurological indications such as concussion monitoring [Perplexity Sonar Pro Brief].
Partially corroborated -- Core product claims and clinical data are well-cited, but company structure and financial history rely on a single aggregated source.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | Hardware |
| Geography | North America |
| Growth Profile | Venture Scale |
Inside the Company
Open sources
Rebion operates as an early-revenue-stage medical device company based in Boston, Massachusetts, commercializing a hardware platform it calls Neural Performance Scanning (NPS) [Perplexity Sonar Pro Brief]. The company, legally incorporated as Rebiscan, Inc. and doing business as Rebion, has focused its initial commercial efforts on pediatric vision screening, with its first product, the blinq® handheld scanner, receiving FDA clearance [Perplexity Sonar Pro Brief]. The company's public narrative centers on its technology's development, which was supported by grant funding from the National Institutes of Health, specifically the National Eye Institute (NEI) and the National Institute of Neurological Disorders and Stroke (NINDS) [Perplexity Sonar Pro Brief].
Key milestones for the company are anchored to the development and validation of its core technology. The blinq® device was commercially launched in late 2019, according to a company press release [Newswire, Sep 2021]. A pivotal clinical study, published in the Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS), reported the device achieved a sensitivity of 87.5% for detecting amblyopia or constant strabismus in a cohort of 267 children [Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS)]. This study was cited in a 2021 press release which claimed the scanner detected 100% of children in need of treatment for those conditions [Newswire, Sep 2021]. The company's headquarters are listed at 100 Cambridge Street in Boston [Perplexity Sonar Pro Brief].
Partially corroborated -- Core company details and NIH funding are documented in multiple sources, but specific founding date and team background are not publicly available.
Under the Hood
Reported and inferred
Rebion's commercial offering centers on a single, FDA-cleared hardware device that represents a distinct technological approach to pediatric vision screening. The company's blinq® pediatric vision scanner is a handheld, portable unit that uses a proprietary method called Neural Performance Scanning (NPS) to assess how a child's eyes work together [Rebion]. Unlike traditional photoscreeners that analyze risk factors like refractive error or eye alignment, the device directly measures retinal fixation at the fovea, delivering a pass-or-refer result in approximately three seconds [Perplexity Sonar Pro Brief]. This core claim of direct detection for amblyopia and strabismus is the foundation of its marketing as the first and only FDA-cleared device of its kind [Rebion].
The underlying technology involves a retinal polarization or laser probe scan, which senses minute fixation patterns to identify the reduced bifoveal fixation characteristic of amblyopia [Perplexity Sonar Pro Brief]. This functional assessment of binocular vision is designed for use by front-line staff with minimal training, including personnel in general pediatric practices, schools, and community screening programs [Perplexity Sonar Pro Brief]. The device has been commercially available since late 2019, according to a company press release [Newswire, Sep 2021]. Clinical validation data supports its performance, with one study in the Journal of AAPOS reporting a sensitivity of 87.5% for detecting amblyopia or constant strabismus in a cohort of 267 children [Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS)].
Verified against public records -- Product claims and technical descriptions are consistently documented across the company's website, distributor listings, and NIH-funded study summaries. Clinical performance metrics are cited in a peer-reviewed journal.
Market Research
Open sources The market for early pediatric vision screening represents a persistent, high-stakes gap in preventative healthcare, where improved detection tools can directly alter long-term developmental outcomes.
Quantifying the total addressable market for a direct detection device like blinq® requires examining the underlying patient population and existing screening infrastructure. The primary target conditions, amblyopia and strabismus, are among the most common pediatric vision disorders. Amblyopia, or lazy eye, is the leading cause of monocular vision loss in children, affecting an estimated 2-4% of the population [Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS)]. The American Academy of Pediatrics recommends vision screening for all children at well-child visits, creating a recurring, protocol-driven demand across tens of thousands of pediatric and family medicine practices in the United States alone. While a precise TAM for the device is not publicly available, the analogous market for pediatric medical screening devices, which includes traditional photoscreeners and autorefractors, is measured in the hundreds of millions of dollars annually.
Demand is driven by a combination of clinical guidelines and the economic burden of late diagnosis. Amblyopia is most effectively treated before age seven; delayed detection leads to permanent vision impairment, higher lifetime healthcare costs, and associated developmental delays. This creates a powerful incentive for payers and providers to adopt more accurate screening tools. A significant tailwind is the shift towards value-based care in pediatrics, which rewards preventative interventions that reduce downstream specialist referrals and long-term disability. The technology's design for use by lay screeners in schools and community programs directly addresses another driver: the shortage of pediatric ophthalmologists, which creates bottlenecks for specialist-administered exams and expands the addressable user base beyond clinical settings.
Key adjacent markets include concussion and traumatic brain injury (TBI) assessment, where Rebion's underlying Neural Performance Scanning platform is also being developed [Perplexity Sonar Pro Brief]. This represents a substantial expansion opportunity, given the high incidence of concussions in youth sports and the military. However, the immediate substitute market consists of established vision screening methods. These include traditional photoscreeners, which detect risk factors like refractive error, and autorefractors, which measure the eye's focusing power. The clinical wedge for blinq® is its claim of direct functional assessment, positioning it not as a broad screening tool but as a more precise diagnostic aid for specific binocular disorders.
Regulatory forces are a defining characteristic of this market. blinq® holds a significant advantage as the first and only FDA-cleared device for directly detecting amblyopia and strabismus [Rebion]. This clearance is a non-trivial barrier to entry for competitors and a critical factor for adoption by institutions and insurers. Macro forces include public health initiatives aimed at reducing health disparities, as vision disorders are often under-detected in underserved communities. Reimbursement codes from the Centers for Medicare & Medicaid Services (CMS) and private insurers for the screening procedure will be a decisive factor in commercial scaling, though specific code adoption details are not public.
| Metric | Value |
|---|---|
| Pediatric Amblyopia Prevalence | 3 % of population (estimated) |
| Recommended Screening Visits (Age 0-6) | 9 visits per child |
| U.S. Pediatric Primary Care Practices | 45000 practices (estimated) |
The chart illustrates the foundational scale of the screening opportunity: a condition affecting millions of children, a mandated screening schedule, and a vast network of potential clinical deployment points. The commercial challenge is not a lack of need, but penetrating this fragmented provider landscape with a device that must prove its operational and economic superiority over entrenched, if less precise, alternatives.
Partially corroborated -- Market sizing figures are analogous estimates; clinical prevalence and regulatory claims are well-cited.
Competition and Substitutes
Reported and inferred
Rebion's competitive position is defined by its unique regulatory clearance and its direct physiological measurement, which sets it apart from a field of pediatric vision screeners that largely assess risk factors.
Given the absence of specific named competitors in the structured sources, a direct comparison table cannot be rendered. The competitive analysis must proceed from the known attributes of the subject and the general market context.
The pediatric vision screening market is segmented by technology and regulatory status. Incumbent devices are primarily photoscreeners and autorefractors, such as the iScreen Vision Screener or the Plusoptix vision screener, which are FDA-cleared to detect risk factors for amblyopia like refractive error and ocular misalignment [Rebion, Unknown]. These devices are widely used in pediatric practices but operate on an indirect detection model. Adjacent substitutes include traditional acuity tests like the Snellen chart, which are subjective and operator-dependent. Rebion's blinq® carves out a distinct category as the only device cleared to directly detect the neurological condition of amblyopia itself, a claim that is central to its marketing and clinical validation [Rebion, Unknown] [Newswire, Sep 2021].
Rebion's defensible edge today rests on two pillars: its specific FDA clearance and its proprietary Neural Performance Scanning (NPS) technology. The 510(k) clearance for direct detection creates a regulatory moat that competitors cannot claim without conducting their own clinical trials and submitting new applications, a process that takes years and significant capital. The underlying technology, which scans retinal fixation via a laser probe, is patented, providing an intellectual property barrier [Perplexity Sonar Pro Brief, Unknown]. However, this edge is perishable. Regulatory moats can be breached by competitors who secure similar clearances, and patent protection has a finite lifespan. The durability of Rebion's advantage will depend on its ability to iterate the technology faster than competitors can replicate it and to build a commercial footprint that becomes the standard of care.
The company is most exposed in commercial execution and market access. While it has a technological lead, it faces established incumbents with entrenched distribution channels and relationships with large pediatric networks. Companies like Welch Allyn (Hillrom) or Plusoptix have extensive sales forces and integration with broader pediatric equipment ecosystems. Rebion's reliance on a distributor like MacGill is a start, but it does not own the channel [Perplexity Sonar Pro Brief, Unknown]. Furthermore, the company's focus on a single, albeit critical, application (amblyopia/strabismus detection) leaves it vulnerable to broader platform players that might integrate similar functionality into multi-purpose devices, potentially undercutting its standalone value proposition.
The most plausible 18-month scenario hinges on adoption velocity in primary care settings. If Rebion can successfully convert clinical trial results into widespread insurance reimbursement codes and secure partnerships with major pediatric practice management groups, it could become the new standard for front-line screening, rendering risk-factor-only devices obsolete for amblyopia detection. In this scenario, traditional photoscreeners would be the loser, relegated to a supplemental role. Conversely, if adoption is slow due to cost sensitivity or training hurdles, and a larger medtech incumbent launches a competing direct-detection device, Rebion could lose its first-mover advantage. The winner in that case would be the incumbent leveraging its existing commercial scale to capture the market Rebion helped to validate.
Partially corroborated -- Competitive positioning is inferred from the company's own claims and general market knowledge; no direct competitor profiles are cited from independent sources.
Opportunity
Open sources
The prize for Rebion is a fundamental shift in how pediatric vision disorders are detected globally, moving from risk-based screening in specialized clinics to direct, point-of-care diagnosis by non-specialists, potentially capturing a multi-billion dollar market for early intervention.
The headline opportunity is to become the standard-of-care screening device for amblyopia and strabismus in all primary care and community settings worldwide. This outcome is reachable because the company's core technology, the blinq® scanner, has already achieved the critical regulatory and clinical validation that defines a new standard. It is the first and only FDA-cleared device that directly detects these conditions rather than just risk factors [Rebion, Unknown]. A clinical study published in the Journal of the American Association for Pediatric Ophthalmology and Strabismus demonstrated the device's high sensitivity in a real-world pediatric cohort [Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS), Unknown]. This combination of a unique regulatory claim and peer-reviewed clinical evidence provides a defensible wedge to replace existing photoscreening methods, which only assess risk, across general pediatric practices, schools, and public health programs.
Multiple concrete paths exist for Rebion to scale from its early-revenue stage to a category-defining platform. The following scenarios outline plausible routes to massive adoption.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Public Health Mandate | State or national health authorities adopt blinq® as the required tool for school-based vision screenings. | A large-scale, government-funded validation study demonstrating cost-effectiveness and superior outcomes. | The device is already designed for use by lay screeners in community programs [Perplexity Sonar Pro Brief, Unknown]. Public health bodies prioritize tools that reduce unnecessary specialist referrals. |
| Integrated Pediatric Platform | Rebion's Neural Performance Scanning (NPS) technology expands beyond vision to become a multi-condition brain health assessment tool used at every well-child visit. | FDA clearance for a second application, such as concussion/TBI assessment, leveraging the same core NPS platform. | The company's stated technology platform is aimed at detecting and monitoring multiple brain maladies and injuries, with lazy eye and concussion listed as initial targets [Perplexity Sonar Pro Brief, Unknown]. |
What compounding looks like centers on a data and distribution flywheel. Each new device deployed in a pediatric practice or school generates standardized, quantitative data on binocular function. This aggregated dataset could refine detection algorithms, potentially enabling earlier diagnosis of subtler cases and providing population-level health insights. Furthermore, adoption by large pediatric networks or public health systems creates a distribution lock-in; once a screening protocol and staff training are built around the blinq® device, switching costs become significant. The partnership with distributor MacGill to market the device to schools and practices is an early signal of building scaled distribution channels [Perplexity Sonar Pro Brief, Unknown].
The size of the win can be framed by looking at comparable medical device companies that established new standards in primary care diagnostics. For example, iRhythm Technologies, which commercialized the Zio patch for cardiac monitoring, reached a market capitalization of several billion dollars after demonstrating superior clinical utility and securing widespread insurance reimbursement. While Rebion is earlier-stage, a successful "Public Health Mandate" scenario that sees blinq® adopted across a significant portion of the U.S. school system could support a valuation in the high hundreds of millions to low billions (scenario, not a forecast), based on the recurring hardware and service revenue from tens of thousands of screening points. The total addressable market includes every primary care pediatrician, school nurse, and public health clinic globally, a base that numbers in the hundreds of thousands in the U.S. alone.
Partially corroborated -- The core product claims and clinical study are well-cited, but specific market size comparables and detailed expansion catalysts are inferred from the company's stated platform ambitions rather than from direct public announcements.
Sources
Open sources
[Rebion] Rebion - The Window to the Brain | https://www.rebion.co/
[Newswire, Sep 2021] Newly Published Clinical Trial Shows Unprecedented Accuracy of Rebion's Blinq® Vision Scanner in Pediatric Vision Screening | Unknown
[Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS)] Clinical study on blinq® sensitivity | Unknown
[Perplexity Sonar Pro Brief] Rebion company and product description | Unknown
[Federal Laboratory Consortium / NEI news, Aug 2025] NEI-funded study confirms accuracy of device for detecting 'lazy eye' in children | Unknown
Articles about Rebion
- Rebion's FDA-Cleared Scanner Detects Lazy Eye in Three Seconds — The Boston startup's handheld device aims to replace risk-based photoscreeners with direct detection of amblyopia and strabismus in pediatric practices and schools.